Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication
Movement Disorders Clinical Practice · 2025-12 · 12 (12) · 2317-2323
DOI: 10.1002/mdc3.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 28.07.2025. Verfasst von Katarina Rukavina und 2 weiteren Autor:innen. Beteiligte Einrichtung: Movement Disorders Hospital Beelitz, Beelitz-Heilstätten, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents, Levodopa, Carbidopa. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Foslevodopa/foscarbidopa (LDp/CDp) significantly reduced motor fluctuations in people with Parkinson's disease (PwP) in clinical trials, but its real‐world tolerability and optimal dosing remain unclear.
Objectives
To assess tolerability, dosing patterns, and modifications to concomitant medication with LDp/CDp in clinical practice.
Methods
A single‐center retrospective cross‐sectional analysis.
Results
The LDp/CDp was initiated in 53 PwP (41% women, mean age 66 ± 11.3 years, mean disease duration 14.1 ± 5.7 years, median H&Y 4 (3–5); history of cognitive impairment: 40%, history of psychosis: 62%, previous device aided therapies failure: 39%). After an optimization period (18.4 ± 6.8 days), the mean Base hourly infusion rate was significantly higher than recommended (0.39 ± 0.18 vs. 0.32 ± 0.13 ml/h, p < 0.001) and the LDp/CDp was co‐administered with MAO‐B‐inhibitors (50%), COMT‐inhibitors (44%), and dopamine agonists (12%). Adverse events occurred in 40%: skin reactions (31%), psychosis (8%), falls (2%), and nausea (2%). Thirteen patients discontinued therapy.
Conclusions
LDp/CDp may be an effective and well‐tolerated non‐surgical option for managing motor fluctuations in PD, though higher dosing and combination therapy are often required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Movement Disorders Hospital Beelitz, Beelitz-Heilstätten, Germany.
- Medical faculty, Health and Medical University Potsdam, Potsdam, Germany.
- Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
ORCID-Profile: Katarina Rukavina
Zitieren
APA
Rukavina, K., Ebersbach, G., & Gruber, D. (2025). Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication. Movement Disorders Clinical Practice, 12(12), 2317-2323. https://doi.org/10.1002/mdc3.70249
Vancouver
Rukavina K, Ebersbach G, Gruber D. Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication. Movement Disorders Clinical Practice. 2025;12(12):2317-2323. doi:10.1002/mdc3.70249
BibTeX
@article{Rukavina2025,
author = {Rukavina, Katarina and Ebersbach, Georg and Gruber, Doreen},
title = {Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication},
journal = {Movement Disorders Clinical Practice},
year = {2025},
volume = {12},
number = {12},
pages = {2317--2323},
doi = {10.1002/mdc3.70249}
}
EUVIMED